Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L E Hjermind

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|October 3, 2000
[Hereditary dystonias]L E Hjermind, S A Sørensen, L M Werdelin
European Journal of Neurology|June 16, 2015
Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's diseaseT Vinther-Jensen, A H Simonsen, E Budtz-Jørgensen, et al.
European Journal of Human Genetics : EJHG|January 29, 2025
Predictive testing for Huntington's disease in a digital age; patient power with potential pitfallsV Mocanu, S G Lindquist, L E Hjermind, et al.
Neurology|May 14, 2003
A novel mutation in the epsilon-sarcoglycan gene causing myoclonus-dystonia syndromeL E Hjermind, L M Werdelin, H Eiberg, et al.
European Journal of Neurology|November 20, 2009
Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitorsK Schultz, K Nilsson, J E Nielsen, et al.
European Journal of Neurology|March 22, 2008
No muscle involvement in myoclonus-dystonia caused by epsilon-sarcoglycan gene mutationsL E Hjermind, J Vissing, F Asmus, et al.
Clinical Genetics|June 18, 2015
Psychiatric and cognitive symptoms in Huntington's disease are modified by polymorphisms in catecholamine regulating enzyme genesT Vinther-Jensen, T T Nielsen, E Budtz-Jørgensen, et al.
Clinical Genetics|June 24, 2011
Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9)H Eiberg, L Hansen, L Korbo, et al.
Clinical Genetics|June 2, 2012
Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion diseaseS G Lindquist, M Duno, M Batbayli, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|October 3, 2000
[Hereditary dystonias]L E Hjermind, S A Sørensen, L M Werdelin
European Journal of Neurology|June 16, 2015
Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's diseaseT Vinther-Jensen, A H Simonsen, E Budtz-Jørgensen, et al.
European Journal of Human Genetics : EJHG|January 29, 2025
Predictive testing for Huntington's disease in a digital age; patient power with potential pitfallsV Mocanu, S G Lindquist, L E Hjermind, et al.
Neurology|May 14, 2003
A novel mutation in the epsilon-sarcoglycan gene causing myoclonus-dystonia syndromeL E Hjermind, L M Werdelin, H Eiberg, et al.
European Journal of Neurology|November 20, 2009
Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitorsK Schultz, K Nilsson, J E Nielsen, et al.
European Journal of Neurology|March 22, 2008
No muscle involvement in myoclonus-dystonia caused by epsilon-sarcoglycan gene mutationsL E Hjermind, J Vissing, F Asmus, et al.
Clinical Genetics|June 18, 2015
Psychiatric and cognitive symptoms in Huntington's disease are modified by polymorphisms in catecholamine regulating enzyme genesT Vinther-Jensen, T T Nielsen, E Budtz-Jørgensen, et al.
Clinical Genetics|June 24, 2011
Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9)H Eiberg, L Hansen, L Korbo, et al.
Clinical Genetics|June 2, 2012
Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion diseaseS G Lindquist, M Duno, M Batbayli, et al.
Pageof 1